We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Myeloma Center

You are here

Clinical characteristics of patients with relapsed multiple myeloma.

TitleClinical characteristics of patients with relapsed multiple myeloma.
Publication TypeJournal Article
Year of Publication2015
AuthorsDimopoulos MA, Terpos E, Niesvizky R, Palumbo A
JournalCancer Treat Rev
Date Published2015 Dec
KeywordsAge Factors, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Humans, Immunologic Factors, Multiple Myeloma, Neoplasm Recurrence, Local, Paraneoplastic Polyneuropathy, Proteasome Inhibitors, Sex Factors

Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients with relapsed MM is challenging given the number and diversity of regimens patients may have previously received, which can affect subsequent therapeutic choices. Importantly, a number of patient- and disease-related factors can also have an effect on treatment choice, treatment efficacy, and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM is important for appropriate treatment selection. Here, we review select patient and disease characteristics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying efficacy and/or tolerability in patients depending on these factors, we also provide treatment recommendations for patients with select baseline characteristics.

Alternate JournalCancer Treat. Rev.
PubMed ID26296679